20 yr outlook.
PFE has a seemingly empty pipeline currently, but they always seem to be relevant in the world of vaccines.
JNJ is terrific, but is next year’s company split going to be a setback to investors?
I own MRK. Trying to determine if adding a new fella in the sector is a good call vs continuing to hit the MRK button. Thoughts?
Leave a Reply